Patents by Inventor Timothy Jon Perlman
Timothy Jon Perlman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11400188Abstract: The present specification discloses plasma processing systems that include a number of different fluid flow circuits that are defined by sources of fluid, fluid lines, fluid flow paths, waste containers, a mixer, a separator, valves, and a pump. The systems also include a connector tube and a solvent extraction device, wherein the connector tube and solvent extraction device are configured to be alternatively inserted in a same position along a fluid flow line. In addition, the systems include a controller that is configured to execute a plurality of programmatic instructions to open and close each of a first fluid flow line valve, a second fluid flow line valve, a third fluid flow line valve, and a fourth fluid flow line valve in a predetermined sequence to either enable or prevent a flow of fluid through various fluid flow lines.Type: GrantFiled: September 4, 2020Date of Patent: August 2, 2022Assignee: HDL Therapeutics, Inc.Inventors: Hollis Bryan Brewer, Jr., Michael M. Matin, Timothy Jon Perlman
-
Patent number: 11027052Abstract: Methods of priming a plasma processing system are disclosed. The plasma processing system has a number of different fluid flow circuits that are defined by sources of fluid, fluid flow paths, waste containers, a mixer, a separator, valves and a pump. A first fluid circuit is flushed, where the first fluid circuit is defined by a source of a first fluid, a first valve positioned between the source of the first fluid and the first fluid flow path, a second valve positioned between the first fluid flow path and the second fluid flow path, a first pump positioned between the second fluid flow path and the third fluid flow path, and a first waste container in fluid communication with the third fluid flow path. A second fluid circuit is then flushed by closing and opening certain valves.Type: GrantFiled: November 21, 2018Date of Patent: June 8, 2021Assignee: HDL Therapuetics, Inc.Inventors: Hollis Bryan Brewer, Michael M. Matin, Timothy Jon Perlman
-
Publication number: 20210121611Abstract: The present specification discloses plasma processing systems that include a number of different fluid flow circuits that are defined by sources of fluid, fluid lines, fluid flow paths, waste containers, a mixer, a separator, valves, and a pump. The systems also include a connector tube and a solvent extraction device, wherein the connector tube and solvent extraction device are configured to be alternatively inserted in a same position along a fluid flow line. In addition, the systems include a controller that is configured to execute a plurality of programmatic instructions to open and close each of a first fluid flow line valve, a second fluid flow line valve, a third fluid flow line valve, and a fourth fluid flow line valve in a predetermined sequence to either enable or prevent a flow of fluid through various fluid flow lines.Type: ApplicationFiled: September 4, 2020Publication date: April 29, 2021Inventors: Hollis Bryan Brewer, JR., Michael M. Matin, Timothy Jon Perlman
-
Publication number: 20210121612Abstract: The present specification discloses plasma processing systems that include a number of different fluid flow circuits that are defined by sources of fluid, fluid lines, fluid flow paths, waste containers, a mixer, a separator, valves, and a pump. The systems also include a connector tube and a solvent extraction device, wherein the connector tube and solvent extraction device are configured to be alternatively inserted in a same position along a fluid flow line. In addition, the systems include a controller that is configured to execute a plurality of programmatic instructions to open and close each of a first fluid flow line valve, a second fluid flow line valve, a third fluid flow line valve, and a fourth fluid flow line valve in a predetermined sequence.Type: ApplicationFiled: September 4, 2020Publication date: April 29, 2021Inventors: Hollis Bryan Brewer, JR., Michael M. Matin, Timothy Jon Perlman
-
Publication number: 20180355021Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: June 8, 2018Publication date: December 13, 2018Inventors: Marc Bellotti, H. Bryan Brewer, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Publication number: 20170174747Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: March 9, 2017Publication date: June 22, 2017Inventors: MARC BELLOTTI, H. BRYAN BREWER, HASSIBULLAH AKEEFE, ADAM PAUL CONNER, TIMOTHY JON PERLMAN
-
Publication number: 20160324925Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: July 20, 2016Publication date: November 10, 2016Inventors: Marc Bellotti, H. Bryan Brewer, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Publication number: 20140107029Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: December 19, 2013Publication date: April 17, 2014Applicant: HDL TherapeuticsInventors: Marc Bellotti, H. Bryan Brewer, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Patent number: 8637460Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: GrantFiled: August 31, 2012Date of Patent: January 28, 2014Assignee: HDL Therapeutics LLCInventors: Marc Bellotti, H. Bryan Brewer, Jr., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Publication number: 20130052167Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: August 31, 2012Publication date: February 28, 2013Applicant: HDL TherapeuticsInventors: Marc BELLOTTI, H. Bryan BREWER, JR., Hassibullah AKEEFE, Adam Paul CONNER, Timothy Jon PERLMAN
-
Patent number: 8268787Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: GrantFiled: August 31, 2011Date of Patent: September 18, 2012Assignee: HDL TherapeuticsInventors: Marc Bellotti, H. Bryan Brewer, Jr., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Publication number: 20110318423Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: August 31, 2011Publication date: December 29, 2011Applicant: HDL THERAPEUTICSInventors: Marc Bellotti, H. Bryan Brewer, JR., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Patent number: 8048015Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: GrantFiled: March 24, 2008Date of Patent: November 1, 2011Assignee: HDL TherapeuticsInventors: Marc Bellotti, H. Bryan Brewer, Jr., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Patent number: 8030281Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: GrantFiled: March 5, 2008Date of Patent: October 4, 2011Assignee: HDL TherapeuticsInventors: Marc Bellotti, H. Bryan Brewer, Jr., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Publication number: 20080230465Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: March 24, 2008Publication date: September 25, 2008Applicant: Lipid Sciences, Inc.Inventors: Marc Bellotti, H. Bryan Brewer, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Publication number: 20080234621Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: March 24, 2008Publication date: September 25, 2008Applicant: Lipid Sciences, Inc.Inventors: Marc Bellotti, H. Bryan Brewer, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Publication number: 20080227726Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: March 5, 2008Publication date: September 18, 2008Inventors: Marc Bellotti, H. Bryan Brewer, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Publication number: 20080214438Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: March 5, 2008Publication date: September 4, 2008Inventors: Marc Bellotti, H. Bryan Brewer, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Patent number: 7393826Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: GrantFiled: October 26, 2005Date of Patent: July 1, 2008Assignee: Lipid Sciences, Inc.Inventors: Marc Bellotti, H. Bryan Brewer, Jr., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Patent number: 7375191Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: GrantFiled: March 8, 2004Date of Patent: May 20, 2008Assignee: Lipid Science, Inc.Inventors: Marc Bellotti, H. Bryan Brewer, Jr., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman